2018年肺癌治疗突破性进展盘点
|
摘要
<正>肺癌是全球癌症主要死因之一,在我国肺癌发病率和死亡率均居首位。近10余年来肺癌治疗突飞猛进、日新月异,2018年也不例外。全年发表于权威期刊和在国际学术会议上具有重大影响力的研究包括:KEYNOTE-189、KEYNOTE-407、KEYNOTE-042、Checkmate227、IMpower130、IMpower131、IMpower132、IMpower150、NEJ026、JO2557等。与此同
引文
[1]Zhou C,Lu Y,Kim SW,et al.Primary results of ALESIA:Arandomised,phaseⅢ,open-label study of alectinib vs crizotinib in Asian patients with treatment-na?ve ALK+adva nced NSCLC[J].Ann Oncol,2018,29(suppl_8).DOI:10.1093/annonc/mdy424.062.
[2]Han B,Li K,Wang Q,et al.Effect of Anlotinib as a ThirdLine or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncol,4(11):1569-1575.
[3]Drilon AE,Subbish V,Oxnaid G,et al.LIBRETTO-001:Aphase 1 study of LOXO-292,a potent and highly selective RETinhibitor,in patients with RET-altered cancers[J].J Clin Oncol,2018,36(15_suppl):102.
[4]Lassen UN,Albert CM,Kummar S,et al.Larotrectinib efficacy and safety in TRK fusion cancer:an expanded clinical dataset showing consistency in an age and tumor agnostic approach[J].Ann Oncol,2018,29(suppl_8).DOI:10.1093/annonc/mdy279.397.
[5]Poziotinib in StageⅣNSCLC With Genetic Mutations[C/OL].WCLC,2018[2019-03-14].http://www.ascopost.com/News/59310.
[6]Zhong WZ.Erlotinib improves progression-free survival in early mutated non-small cell lung cancer[C/OL].Munich:ESMO,2018.
[7]Yue D,Xu S,Wang Q,et al.Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stageⅢAEGFR mutation-positive non-small-cell lung cancer(EVAN):a randomised,open-label,phase 2 trial[J].Lancet Respir Med,2018,6(11):863-873.
[8]Gandhi L,Rodríguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(22):2078-2092.
[9]Paz-Ares L,Luft A,Vicente D,et al.Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,379(21):2040-2051.
[10]Lopes G,Wu YL,Kudaba I,et al.Pembrolizumab(pembro)versus platinum-based chemotherapy(chemo)as firstline therapy for advanced/metastatic NSCLC with a PD-L1tumor proportion score(TPS)≥1%:Open-label,phase 3KEYNOTE-042 study[J].J Clin Oncol,2018,36(18_suppl).DOI:10.1200/JCO.2018.36.18_suppl.LBA4.
[11]Wu YL,Lu S,Cheng Y,et al.Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer:Check Mate078 Randomized Phase Ⅲ Clinical Trial[J].J Thoracic Oncol,2019.DOI:10.1016/j.jtho.2019.01.006.
[12]Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J].N Engl J Med,2018,378(22):2093-2104.
[13]Cappuzzo F.IMpower130:Progression-free survival(PFS)and safety analysis from a randomised phase 3 study of carboplatin+nab-paclitaxel(Cn P)with or without atezolizumab(atezo)as first-line(1L)therapy in advanced non-squamous NSCLC[C].Munich:ESMO,2018.
[14]Socinski MA,Jotte RM,Cappuzzo F,et al.Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC[J].NEngl J Med,2018,378(24):2288-2301.
[15]Robert MJ,Cappuzzo F,Vynnychenko I,et al.IMpower131:Primary PFS and safety analysis of a randomized phaseⅢstudy of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitaxel as 1L therapy in advanced squamous NSCLC[J].J Clin Oncol,2018,36(18_suppl).DOI:10.1200/JCO.2018.36.18_suppl.LBA9000.
[16]Furuya N,Fukuhara T,Saito H,et al.Phase Ⅲ study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations:NEJ026[J].JClin Oncol,2018,36(15_suppl):9006.
[17]Cheng Y.PhaseⅡALTER1202:Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond[C].Toronto:WCLC,2018.
[2]Han B,Li K,Wang Q,et al.Effect of Anlotinib as a ThirdLine or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncol,4(11):1569-1575.
[3]Drilon AE,Subbish V,Oxnaid G,et al.LIBRETTO-001:Aphase 1 study of LOXO-292,a potent and highly selective RETinhibitor,in patients with RET-altered cancers[J].J Clin Oncol,2018,36(15_suppl):102.
[4]Lassen UN,Albert CM,Kummar S,et al.Larotrectinib efficacy and safety in TRK fusion cancer:an expanded clinical dataset showing consistency in an age and tumor agnostic approach[J].Ann Oncol,2018,29(suppl_8).DOI:10.1093/annonc/mdy279.397.
[5]Poziotinib in StageⅣNSCLC With Genetic Mutations[C/OL].WCLC,2018[2019-03-14].http://www.ascopost.com/News/59310.
[6]Zhong WZ.Erlotinib improves progression-free survival in early mutated non-small cell lung cancer[C/OL].Munich:ESMO,2018.
[7]Yue D,Xu S,Wang Q,et al.Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stageⅢAEGFR mutation-positive non-small-cell lung cancer(EVAN):a randomised,open-label,phase 2 trial[J].Lancet Respir Med,2018,6(11):863-873.
[8]Gandhi L,Rodríguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(22):2078-2092.
[9]Paz-Ares L,Luft A,Vicente D,et al.Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,379(21):2040-2051.
[10]Lopes G,Wu YL,Kudaba I,et al.Pembrolizumab(pembro)versus platinum-based chemotherapy(chemo)as firstline therapy for advanced/metastatic NSCLC with a PD-L1tumor proportion score(TPS)≥1%:Open-label,phase 3KEYNOTE-042 study[J].J Clin Oncol,2018,36(18_suppl).DOI:10.1200/JCO.2018.36.18_suppl.LBA4.
[11]Wu YL,Lu S,Cheng Y,et al.Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer:Check Mate078 Randomized Phase Ⅲ Clinical Trial[J].J Thoracic Oncol,2019.DOI:10.1016/j.jtho.2019.01.006.
[12]Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J].N Engl J Med,2018,378(22):2093-2104.
[13]Cappuzzo F.IMpower130:Progression-free survival(PFS)and safety analysis from a randomised phase 3 study of carboplatin+nab-paclitaxel(Cn P)with or without atezolizumab(atezo)as first-line(1L)therapy in advanced non-squamous NSCLC[C].Munich:ESMO,2018.
[14]Socinski MA,Jotte RM,Cappuzzo F,et al.Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC[J].NEngl J Med,2018,378(24):2288-2301.
[15]Robert MJ,Cappuzzo F,Vynnychenko I,et al.IMpower131:Primary PFS and safety analysis of a randomized phaseⅢstudy of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitaxel as 1L therapy in advanced squamous NSCLC[J].J Clin Oncol,2018,36(18_suppl).DOI:10.1200/JCO.2018.36.18_suppl.LBA9000.
[16]Furuya N,Fukuhara T,Saito H,et al.Phase Ⅲ study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations:NEJ026[J].JClin Oncol,2018,36(15_suppl):9006.
[17]Cheng Y.PhaseⅡALTER1202:Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond[C].Toronto:WCLC,2018.